Last reviewed · How we verify
1100 ppm NaF Fluoride Dentifrice
1100 ppm NaF Fluoride Dentifrice is a Small molecule drug developed by Procter and Gamble. It is currently in Phase 1 development.
At a glance
| Generic name | 1100 ppm NaF Fluoride Dentifrice |
|---|---|
| Sponsor | Procter and Gamble |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- ORAL MUCOSAL EXFOLIATION
- MOUTH INJURY
- Common cold
- Cellulitis Orbital
- Pneumonia
- TONGUE ULCERATION
- HYPERAESTHESIA TEETH
- ORAL DISCOMFORT
- Headache
- Oral Mucosal Erthyema
- Nasopharyngitis
- Erythema Mandibular Ridge
Key clinical trials
- Clinical Research Study to Assess the Efficacy of Two Brushing Regimens in the Reduction of Established Dental Plaque and Gingivitis. (PHASE3)
- A Clinical Study Investigating the Effect of an Experimental Toothpaste Containing Stannous Fluoride in Improving Gingival Health (NA)
- A Clinical Study Assessing the Effects of a Marketed Dentifrice on Tooth Sensitivity While Undergoing Tooth Bleaching (PHASE4)
- A Study to Evaluate the Effect of a Stannous Fluoride Toothpaste on the Oral Microbiome (NA)
- In Situ Comparison of the Remineralization Potential of Optimized Fluoride Dentifrice With Control Fluoride Dentifrice (PHASE3)
- Clinical Study to Investigate the Ability of a Stannous Fluoride Toothpaste to Protect From Dentine Hypersensitivity (NA)
- Probiotics That Moderate pH and Antagonize Pathogens to Promote Oral Health (NA)
- A Clinical Trial to Assess the Safety and the Anti-caries Efficacy of COL 101 (Arginine) Non-fluoride Dentifrices in Comparison With 0.24% Sodium Fluoride (1100 Ppm F) Dentifrice Control in 10 to 14-year-old Children (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 1100 ppm NaF Fluoride Dentifrice CI brief — competitive landscape report
- 1100 ppm NaF Fluoride Dentifrice updates RSS · CI watch RSS
- Procter and Gamble portfolio CI
Frequently asked questions about 1100 ppm NaF Fluoride Dentifrice
What is 1100 ppm NaF Fluoride Dentifrice?
1100 ppm NaF Fluoride Dentifrice is a Small molecule drug developed by Procter and Gamble.
Who makes 1100 ppm NaF Fluoride Dentifrice?
1100 ppm NaF Fluoride Dentifrice is developed by Procter and Gamble (see full Procter and Gamble pipeline at /company/procter-and-gamble).
What development phase is 1100 ppm NaF Fluoride Dentifrice in?
1100 ppm NaF Fluoride Dentifrice is in Phase 1.
What are the side effects of 1100 ppm NaF Fluoride Dentifrice?
Common side effects of 1100 ppm NaF Fluoride Dentifrice include ORAL MUCOSAL EXFOLIATION, MOUTH INJURY, Common cold, Cellulitis Orbital, Pneumonia, TONGUE ULCERATION.